Literature DB >> 17298709

Comparison of composition and absorption of sugarcane policosanols.

Christopher P F Marinangeli1, Amira N Kassis, Deepak Jain, Naoyuki Ebine, Stephen C Cunnane, Peter J H Jones.   

Abstract

Policosanols (PC) exist as very-long-chain alcohols derived from sugarcane currently used in many countries as a cholesterol-lowering therapy. PC purity and relative percentage composition have been suggested as primary reasons why the original Cuban PC (OPC) supplements possess lipid-lowering efficacy. The purpose of the present study was, first, to compare the relative percentage purity and PC composition of both OPC and alternative sources of PC (APC). A second objective was to feed Syrian hamsters a diet containing 0.275 mg PC/g of either the OPC or an APC product (APC1) and compare subsequent tissue, plasma and faecal PC levels. Five animals from the APC1 dietary group received a diet containing ten times the original amount of PC. Results indicate that the APC formulations have a composition that is highly consistent with the OPC supplement, with octacosanol being present within the cited 60-70 % range. PC were undetectable in the small intestine, liver, adipose or plasma in animals fed either source. Hamsters fed OPC excreted octacosanol (C28) more rapidly (P < 0.05) than hamsters receiving APC1. If the cholesterol-lowering efficacy of PC mixtures is dependent on their purity and composition, then sugarcane-derived APC products should possess similar therapeutic properties as the OPC supplement.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17298709     DOI: 10.1017/S0007114507336763

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  8 in total

1.  Modified-policosanol does not reduce plasma lipoproteins in hyperlipidemic patients when used alone or in combination with statin therapy.

Authors:  James M Backes; Cheryl A Gibson; Janelle F Ruisinger; Patrick M Moriarty
Journal:  Lipids       Date:  2011-07-08       Impact factor: 1.880

2.  Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection.

Authors:  Shawn A Ritchie; Pearson W K Ahiahonu; Dushmanthi Jayasinghe; Doug Heath; Jun Liu; Yingshen Lu; Wei Jin; Amir Kavianpour; Yasuyo Yamazaki; Amin M Khan; Mohammad Hossain; Khine Khine Su-Myat; Paul L Wood; Kevin Krenitsky; Ichiro Takemasa; Masakazu Miyake; Mitsugu Sekimoto; Morito Monden; Hisahiro Matsubara; Fumio Nomura; Dayan B Goodenowe
Journal:  BMC Med       Date:  2010-02-15       Impact factor: 8.775

3.  Octacosanol administration to humans decreases neutral sterol and bile acid concentration in feces.

Authors:  Sylvia Keller; Franziska Gimmler; Gerhard Jahreis
Journal:  Lipids       Date:  2007-11-15       Impact factor: 1.880

4.  Sugar cane policosanols do not reduce LDL oxidation in hypercholesterolemic individuals.

Authors:  Amira N Kassis; Stan Kubow; Peter J H Jones
Journal:  Lipids       Date:  2009-04-01       Impact factor: 1.880

Review 5.  Nutraceutical Vegetable Oil Nanoformulations for Prevention and Management of Diseases.

Authors:  Cristian Vergallo
Journal:  Nanomaterials (Basel)       Date:  2020-06-24       Impact factor: 5.076

6.  Potential role of phytochemicals in metabolic syndrome prevention and therapy.

Authors:  Francesco Francini-Pesenti; Paolo Spinella; Lorenzo A Calò
Journal:  Diabetes Metab Syndr Obes       Date:  2019-10-01       Impact factor: 3.168

7.  Cuban Sugar Cane Wax Acid and Policosanol Showed Similar Atheroprotective Effects with Inhibition of LDL Oxidation and Cholesteryl Ester Transfer via Enhancement of High-Density Lipoproteins Functionality.

Authors:  Kyung-Hyun Cho; Myung-Ae Bae; Jae-Ryong Kim
Journal:  Cardiovasc Ther       Date:  2019-02-24       Impact factor: 3.023

8.  Changes in cholesterol kinetics following sugar cane policosanol supplementation: a randomized control trial.

Authors:  Amira N Kassis; Peter J H Jones
Journal:  Lipids Health Dis       Date:  2008-04-30       Impact factor: 3.876

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.